NASDAQ
Revelation Biosciences, Inc. (REVB)
♥ 604 Thanks from members
Revelation Biosciences, Inc. (REVB) exhibits speculative micro-cap sentiment characterized by pre-revenue status, ongoing cash runway concerns extending to Q1 2027, and planned Phase 2/3 GEM-AKI trial catalysts, offset by weak fundamental valuation models and negative AI scores.